175 related articles for article (PubMed ID: 37751310)
1. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
Tamhankar MA; Pradeep T; Chen Y; Briceño CA
J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
[TBL] [Abstract][Full Text] [Related]
2. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.
Sears CM; Wang Y; Bailey LA; Turbin R; Subramanian PS; Douglas R; Cockerham K; Kossler AL
Am J Ophthalmol Case Rep; 2021 Sep; 23():101111. PubMed ID: 34113737
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy.
Sears CM; Azad AD; Dosiou C; Kossler AL
Ophthalmic Plast Reconstr Surg; 2021 May-Jun 01; 37(3S):S157-S160. PubMed ID: 32976335
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
9. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
Hwang CJ; Nichols EE; Chon BH; Perry JD
Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy.
Lu TJ; Amarikwa L; Sears CM; Kossler AL
Curr Neurol Neurosci Rep; 2022 Jun; 22(6):313-325. PubMed ID: 35614367
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
[TBL] [Abstract][Full Text] [Related]
13. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
Ugradar S; Kossler AL; Douglas R; Cockerham K
J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
[TBL] [Abstract][Full Text] [Related]
14. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
Mudalegundi S; Huang P; Henderson AD; Carey AR
J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.
Rezar-Dreindl S; Papp A; Baumann A; Neumayer T; Eibenberger K; Stifter E; Schmidt-Erfurth U
Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3683-3691. PubMed ID: 35731314
[TBL] [Abstract][Full Text] [Related]
16. Combined endonasal and orbital approach for annulus of Zinn area decompression in dysthyroid optic neuropathy.
Yinghong Z; Jichao Z; Zhidi Z; Chiyu X; Haipeng Z; Yanrong R; Li Z; Yi W
Am J Otolaryngol; 2023; 44(2):103692. PubMed ID: 36473262
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
Subramanian PS; Cho RI; Kahana A
Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
[TBL] [Abstract][Full Text] [Related]
18. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators.
Douglas RS; Wang Y; Dailey RA; Harris GJ; Wester ST; Schiffman JS; Tang RA; Fowler B; Fleming J; Smith TJ
J Neuroophthalmol; 2021 Dec; 41(4):461-468. PubMed ID: 33417417
[TBL] [Abstract][Full Text] [Related]
20. Comparison of surgical effect in active and inactive Dysthyroid Optic Neuropathy after Endoscopic Transnasal Medial Orbital Decompression.
Lv X; Gao Y; Ma Y; Li C; Ren Y; Zhang Z; Bao Y; Su S; Lu R
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):281-293. PubMed ID: 37530848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]